1. [Modulation of the incretin effect in the treatment of diabetes].
- Author
-
Vidal J
- Subjects
- Clinical Trials as Topic, Diabetes Mellitus, Type 2 enzymology, Diabetes Mellitus, Type 2 physiopathology, Dipeptidyl Peptidase 4 physiology, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Dipeptidyl-Peptidase IV Inhibitors pharmacology, Gastrointestinal Motility drug effects, Gastrointestinal Motility physiology, Glucagon-Like Peptide 1 blood, Glucagon-Like Peptide 1 metabolism, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents adverse effects, Hypoglycemic Agents pharmacology, Models, Biological, Precision Medicine, Spain, Diabetes Mellitus, Type 2 drug therapy, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Glucagon-Like Peptide 1 agonists, Hypoglycemic Agents therapeutic use, Incretins agonists, Receptors, Glucagon agonists
- Abstract
Modulation of the incretin effect has opened up a new strategy in the treatment of diabetes mellitus type 2 (DM2). To date, this physiological mechanism has been boosted in two ways: firstly, by pharmacological inhibition of the enzyme that physiologically degrades glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP4); secondly, through the development of GLP-1 agonists (GLP-1a) that are resistant to the action of DPP-4. Several clinical trials have shown the clinical superiority of GLPa, which seems to be linked to higher circulating levels of GLP-1. On the other hand, this higher efficacy also seems to be associated with the higher rate of adverse effects associated with aGLP-1 therapy compared with DPP-4 inhibition. These and other differentiating characteristics of the two drug families will determine the choice of drug therapy in the personalized treatment of hyperglycemia in patients with DM2., (Copyright © 2014 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF